Graybug is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve. The company’s proprietary ocular delivery technologies are designed to maintain effective drug levels in ocular tissue for six months and potentially longer, improving disease management, reducing healthcare burdens and ultimately delivering better clinical outcomes. Graybug’s lead product candidate, GB-102, a formulation of the pan-vascular endothelial growth factor (VEGF) inhibitor, sunitinib malate targeting a six-month or longer dosing regimen, inhibits multiple neovascular pathways for the intravitreal treatment of retinal diseases, including wet age-related macular degeneration. Graybug’s other product candidates developed using its proprietary technologies also include GB-401, an injectable sustained-release formulation of a beta-adrenergic blocker prodrug, for primary open-angle glaucoma, with a dosing regimen of once every six months or longer. Founded in 2011 on the basis of technology licensed from the Johns Hopkins University School of Medicine, the company has offices in Baltimore, Maryland, and Redwood City, California.
Launched in 1994, Deerfield Management Company is an investment firm dedicated to advancing healthcare through information, investment, and philanthropy—all toward the end goal of cures for disease, improved quality of life, and reduced cost of care.
Read More
Investment
Supporting companies across the healthcare ecosystem with flexible funding models…
Read MoreInfrastructure of Support
Cure, Deerfield’s Innovation Campus Deerfield Discovery & Development External Operations
Research Collaborations
Deerfield partners with leading academic research centers, providing critical funding and expertise to further sustain and accelerate the commercialization of discoveries toward meaningful societal impact by advancing cures for disease.
Read More
Strategic Partners
As a strategic partner, Deerfield offers capital, scientific expertise, business operating support, and unique access to innovation.
Deerfield Foundation
The Deerfield Foundation is a New York City-based not-for-profit organization whose mission is to improve health, accelerate innovation and promote human equity.
Read More Meet the Foundation TeamFoundation Partners by Focus
Children's Health Diversity Initiatives Maternal Health View AllFounded Diversity Programs
Break into the Boardroom Fellowships Women in Science
Cure Campus
Cure is a 12-story innovations campus in New York City that intends to bring together innovators from academia, government, industry, and the not-for-profit sectors to advance human health and accelerate the fight against disease.
Read More Meet the Cure Team Join the Cure Email ListCure Programming
Cure has a series of expert lectures intended to advance thought in healthcare, management, innovation, policy, and other relevant subjects. This fosters growth and education for those at Cure and its guests.
Events at the Cure